PALO ALTO, CA - I. Craig Henderson, M.D. has been named Chairman of the Board of PrognosDx Health effective January 16th, 2014. Dr. Henderson has an extensive career in treatment of breast cancer patients and welcomes the opportunity to help move forward the company’s prognostic tests for breast, prostate and other cancers. Joe Vallner, PhD, CEO of PrognosDx said: “Dr. Henderson’s reputation as an industry executive with expertise in the field of oncology will pay large dividends to our company in the future as we seek to get widespread adoption of our prognostic tests for cancer patients”.
Dr. Henderson has extensive experience in the biotechnology and pharmaceutical industry having been CEO and/or President of 3 companies. He developed an intimate knowledge of the regulatory processes as a member and chairman of the FDA’s Oncology Drug Advisory Committee (ODAC). He has had a distinguished academic career, first at Harvard and more recently at the University of California, San Francisco, where he conducted clinical trials and led bed to bedside translational research programs. He has expertise in the development and assessment of laboratory tests; in 2011/12 he served as a member of the Institute of Medicine (National Academy of Science) committee on the development of “omics” tests for the development of prognostic and predictive assays for the management of cancer patients.
From 1995 – 1999 Dr. Henderson was Chairman and CEO of SEQUUS Pharmaceuticals in Menlo Park, California where he led the development and launch of Doxil, a drug that eventually had peak worldwide sales in excess of $700M. In 1999 SEQUUS was merged with Alza, and Dr. Henderson became a senior consultant and a member of the Alza Board. In 2000 he was the co-founder and later became the CEO and President of a new biotechnology company, Access Oncology, Inc. (AOI). In 2004 AOI was merged with Keryx Biopharmaceuticals, and Dr. Henderson continued as President of the combined entity until April of 2008. He currently works as a consultant to various biotechnology and pharmaceutical companies with a focus on the development of long-term clinical, regulatory and marketing strategies.
Over the course of his career Dr. Henderson has been involved in raising >$300 M on Wall Street, has managed companies with employees ranging from 5 to >250 employees, led dozens of national and international trials (including the pivotal phase II trial of Herceptin), developed a proprietary trial network of 450 community based oncologists that enrolled >1500 patients on drug trials in a 3-year span, has served for >20 years on the Blue Cross/Blue Shield National Association’s Medical Advisory Panel, served 2 terms as a member of the Medicare Coverage Advisory Committee (MedCAC), founded one of the first multi-disciplinary breast programs while he was at the Dana-Farber Cancer Institute, has published nearly 300 books and papers, lectured widely on the treatment of cancer and development of new therapy, and had multiple appearances on regional and national television shows including the Today Show, 60 Minutes and 20/20. He continues as a member of the UCSF faculty.
About PrognosDx:
PrognosDx is a biotechnology company committed to eliminating the trial and error approach to cancer treatment through analysis of global histone modifications. The company is supported by world class advisors. More than 20 published international studies support the role of histone biomarkers for clinical prognosis of patients in many cancers. PrognosDx has entered into a broad collaboration agreement with Molecular Medicine Research Institute, Sunnyvale, CA which provides the company lab and office space.
Help employers find you! Check out all the jobs and post your resume.
